Literature DB >> 28662748

Institutional Oversight of Occupational Health and Safety for Research Programs Involving Biohazards.

Melissa C Dyson1, Calvin B Carpenter2, Lesley A Colby3.   

Abstract

Research with hazardous biologic materials (biohazards) is essential to the progress of medicine and science. The field of microbiology has rapidly advanced over the years, partially due to the development of new scientific methods such as recombinant DNA technology, synthetic biology, viral vectors, and the use of genetically modified animals. This research poses a potential risk to personnel as well as the public and the environment. Institutions must have appropriate oversight and take appropriate steps to mitigate the risks of working with these biologic hazards. This article will review responsibilities for institutional oversight of occupational health and safety for research involving biologic hazards.

Mesh:

Substances:

Year:  2017        PMID: 28662748      PMCID: PMC5482511     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  24 in total

1.  Risks and benefits, rights and responsibilities: a history of the recombinant DNA research controversy.

Authors:  Judith P Swazey; James R Sorenson; Cynthia B Wong
Journal:  South Calif Law Rev       Date:  1978-09

Review 2.  Evidence-based biosafety: a review of the principles and effectiveness of microbiological containment measures.

Authors:  Tjeerd G Kimman; Eric Smit; Michèl R Klein
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

3.  Survey of laboratory-acquired infections.

Authors:  S E SULKIN; R M PIKE
Journal:  Am J Public Health Nations Health       Date:  1951-07

4.  Personal reflections on the origins and emergence of recombinant DNA technology.

Authors:  Paul Berg; Janet E Mertz
Journal:  Genetics       Date:  2010-01       Impact factor: 4.562

5.  Implementing a medical surveillance program for animal care staff.

Authors:  Debra Sharpe
Journal:  Lab Anim (NY)       Date:  2009-08       Impact factor: 12.625

6.  Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

Authors:  R J Jackson; A J Ramsay; C D Christensen; S Beaton; D F Hall; I A Ramshaw
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

7.  Laboratory infections with louping-ill virus.

Authors:  H W Reid; C A Gibbs; C Burrells; P C Doherty
Journal:  Lancet       Date:  1972-03-11       Impact factor: 79.321

Review 8.  Biological Risks and Laboratory-Acquired Infections: A Reality That Cannot be Ignored in Health Biotechnology.

Authors:  Ana Cláudia Coelho; Juan García Díez
Journal:  Front Bioeng Biotechnol       Date:  2015-04-28

9.  Diffusion of synthetic biology: a challenge to biosafety.

Authors:  Markus Schmidt
Journal:  Syst Synth Biol       Date:  2008-07-09

Review 10.  General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination.

Authors:  Aline Baldo; Eric van den Akker; Hans E Bergmans; Filip Lim; Katia Pauwels
Journal:  Curr Gene Ther       Date:  2013-12       Impact factor: 4.391

View more
  5 in total

1.  Special Issue: Infectious Disease Research: Animal Models and Risk Management.

Authors:  Jason S Villano; Bryan E Ogden
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

2.  COVID-19 and Animal-Based Research.

Authors:  Jason S Villano
Journal:  Comp Med       Date:  2021-10-01       Impact factor: 0.982

Review 3.  Environmental Health and Biosafety Risk Assessment Guidance for Commercial-Scale Cell and Gene Therapy Manufacturing.

Authors:  Kimberly DiGiandomenico; Erin Dunn; Cari Sadowski; Simon Godwin; Maureen Keeler; Francine Preston; Patrick Niven; Phillip Ramsey; Helen Hay
Journal:  Appl Biosaf       Date:  2020-12-01

4.  Preclinical coronavirus studies and pathology: Challenges of the high-containment laboratory.

Authors:  Victoria K Baxter; Stephanie A Montgomery
Journal:  Vet Pathol       Date:  2022-04-11       Impact factor: 3.157

5.  COVID-19 Impact on Musculoskeletal Regenerative Medicine Research: Maintaining Lab Continuity.

Authors:  Livia Roseti; Brunella Grigolo
Journal:  Int J Environ Res Public Health       Date:  2021-06-05       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.